Oncternal Therapeutics Inc. (ONCT) Reports Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 Oct 22, 2024 09:01AM
Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer Oct 22, 2024 09:00AM
Oncternal Therapeutics (ONCT) Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives Sep 12, 2024 09:01AM
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives Sep 12, 2024 09:00AM